Veru Inc. experienced a dramatic surge in its stock price on Thursday, with shares more than doubling after announcing a clinical supply agreement with Novo Nordisk for its obesity treatment trial. The small-cap biotechnology company saw its stock jump 112% to $4.78 in afternoon trading, recovering from an earlier high of $7.04. Trading volume reached approximately 69.4 million shares, far exceeding typical levels, and the company's market capitalization stood at roughly $76.7 million.
Details of the Agreement
According to a June 4 SEC filing, Novo Nordisk will supply its blockbuster GLP-1 drug Wegovy (semaglutide) at no cost for Veru's Phase 2b PLATEAU obesity trial. Veru will retain full sponsorship and conduct the study independently. Under the terms, Veru keeps worldwide rights to develop and commercialize enobosarm, but grants Novo Nordisk a right of first negotiation should Veru seek to develop, market, or license enobosarm in combination with any Novo GLP-1 therapy, including Wegovy.
Analyst Reactions
Analysts viewed the deal as a major validation. Oppenheimer's Leland Gershell called it "external validation" for Veru's combination and oral maintenance strategy, reiterating an Outperform rating and $24 price target. Canaccord Genuity maintained a Buy rating and $25 target, describing the agreement as a "significant event" that demonstrates enobosarm has "grabbed the attention" of a leading obesity company.
Strategic Positioning
Veru is targeting a niche within the weight-loss market, aiming to preserve muscle and lean tissue in older patients using GLP-1 medications. The company's enobosarm is designed to complement drugs like Wegovy and Eli Lilly's Zepbound, rather than compete directly. The PLATEAU trial is enrolling approximately 200 patients aged 65 and older with a BMI of 35 or more who are initiating semaglutide therapy. The primary endpoint is percent change in total body weight at 68 weeks, with secondary measures including fat mass, lean mass, physical function, and bone mineral density.
Upcoming Milestones
Veru stated in May that patient enrollment is underway, with an interim analysis expected in the first quarter of 2027. CEO Mitchell Steiner confirmed the company is "on track for presenting" the interim data. Louis Aronne, an obesity specialist and Veru scientific adviser, noted that future weight-loss drugs will likely involve GLP-1 combinations that preserve lean mass, positioning the PLATEAU study as key for Phase 3 planning.
Risks and Challenges
Despite the positive market reaction, Veru cautioned that the trial may not meet its endpoints, the FDA could push back on later study designs, and enrollment may face delays. Novo Nordisk can terminate the supply agreement with 60 days' notice. Additionally, Veru acknowledged it will need to secure financing to support its operations. Reimbursement uncertainty for GLP-1 drugs remains a concern, exemplified by Cigna's recent announcement that it will stop covering Wegovy and Zepbound for its employees starting July 1.
Market Context
The stock's dramatic move reflects investor enthusiasm over the Novo Nordisk partnership, but the company is still in early-stage development with no approved obesity drug. The deal provides external validation and access to Wegovy at no cost, but the path to commercialization remains uncertain. Analysts' price targets of $24-$25 suggest significant upside from current levels, but achieving those targets will depend on positive clinical data and successful navigation of regulatory and reimbursement hurdles.
